Tang Bin-Can, Wang Ya-Ting, Ren Jie
Department of Anesthesiology Southwest Medical University Luzhou China.
Department of Neuroscience The University of Sheffield Sheffield UK.
Ibrain. 2023 Jun 6;9(3):340-348. doi: 10.1002/ibra.12098. eCollection 2023 Fall.
Memantine is a noncompetitive moderate-affinity strong voltage-dependent N-methyl-D-aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world. AD is nonreversible, and memantine can only relieve the symptoms of AD but not cure it. Over the past half-century, memantine's research and clinical application have been extensively developed. In this review, the basic composition of memantine, the mechanism and limitations of memantine in the treatment of AD, memantine combination therapy, comparison of memantine with other drugs for AD, and clinical studies of memantine in other diseases are reviewed to provide a valuable reference for further research and application of memantine for the treatment of AD.
美金刚是一种非竞争性、中等亲和力、强电压依赖性N-甲基-D-天冬氨酸受体拮抗剂。自1989年以来，它一直被用于治疗阿尔茨海默病（AD）。2018年，它成为全球第二常用的痴呆治疗药物。AD是不可逆的，美金刚只能缓解AD的症状而不能治愈它。在过去的半个世纪里，美金刚的研究和临床应用得到了广泛发展。在这篇综述中，对美金刚的基本成分、美金刚治疗AD的机制和局限性、美金刚联合治疗、美金刚与其他AD治疗药物的比较以及美金刚在其他疾病中的临床研究进行了综述，为美金刚进一步用于AD治疗的研究和应用提供有价值的参考。
